{"id":556994,"date":"2021-08-10T18:26:01","date_gmt":"2021-08-10T18:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=556994"},"modified":"2021-08-10T18:26:01","modified_gmt":"2021-08-10T18:26:01","slug":"psoriatic-arthritis-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/psoriatic-arthritis-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_556994.html","title":{"rendered":"Psoriatic Arthritis Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis By DelveInsight"},"content":{"rendered":"
\n
\"Psoriatic<\/a><\/div>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u2018Psoriatic Arthritis (PsA)\u2013 Market Insights, Epidemiology, and Market Forecast\u20142030\u2019 report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Psoriatic Arthritis in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.<\/p>\n<\/div>\n

DelveInsight has launched a new report on“Psoriatic Arthritis – Market Insights, Epidemiology, and Market Forecast-2030”.<\/a><\/strong><\/p>\n

DelveInsight’s “Psoriatic Arthritis – Market Insights, Epidemiology, and Market Forecast-2030″<\/a>report delivers an in-depth understanding of the Psoriatic Arthritis, historical and forecasted epidemiology as well as the Psoriatic Arthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

\"\"<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    According to a study, almost a third of patients with psoriasis seen in dermatology centers had PsA as determined by rheumatologists.<\/p>\n<\/li>\n

  2. \n

    According to a study of German healthcare insurance data, PsA had prevalence rates of 0.3% respectively, in 2016.<\/p>\n<\/li>\n

  3. \n

    Psoriatic Arthritis was identified in 431 of 3021 patients with psoriasis, with a mean prevalence of 14.3% (range, 8.8–20.4%)  in Japan.<\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

      \n
    1. \n

      Psoriatic Arthritis  market report covers a descriptive overview and comprehensive insight of the Psoriatic Arthritis  epidemiology and Psoriatic Arthritis  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n<\/li>\n

    2. \n

      The Psoriatic Arthritis market report provides insights on the current and emerging therapies.<\/p>\n<\/li>\n

    3. \n

      Psoriatic Arthritis market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n<\/li>\n

    4. \n

      The Psoriatic Arthritis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Psoriatic Arthritis market.<\/p>\n<\/li>\n<\/ol>\n

      Got queries? Click here to know more about the Psoriatic Arthritis Market Landscape.<\/a><\/strong><\/p>\n

      Psoriatic Arthritis Overview<\/strong><\/p>\n

      Psoriatic Arthritis is a sort of arthritis that affects some people with psoriasis. Most people develop psoriasis first and are later diagnosed with psoriatic arthritis, but joint problems can sometimes begin before skin patches appear.<\/p>\n

      The key players involved in the Psoriatic Arthritis  market:<\/strong><\/p>\n

        \n
      1. \n

        AbbVie<\/p>\n<\/li>\n

      2. \n

        Sun Pharma<\/p>\n<\/li>\n

      3. \n

        Bristol-Myers Squibb<\/p>\n<\/li>\n

      4. \n

        UCB Biopharma<\/p>\n<\/li>\n

      5. \n

        Pfizer<\/p>\n<\/li>\n

      6. \n

        And others.<\/p>\n<\/li>\n<\/ol>\n

        The launch of the emerging therapies is expected to significantly impact the Psoriatic Arthritis treatment scenario in the upcoming years:-<\/strong><\/p>\n

        Drug covered<\/strong><\/p>\n

          \n
        1. \n

          Skyrizi and Rinvoq <\/p>\n<\/li>\n

        2. \n

          Ilumya  <\/p>\n<\/li>\n

        3. \n

          Deucravacitinib<\/p>\n<\/li>\n

        4. \n

          Bimekizumab<\/p>\n<\/li>\n

        5. \n

          Brepocitinib<\/p>\n<\/li>\n

        6. \n

          And others.<\/p>\n<\/li>\n<\/ol>\n

          Table of Contents<\/strong><\/p>\n

          1. Report Introduction<\/p>\n

          2. Executive Summary<\/p>\n

          3. SWOT analysis<\/p>\n

          4. Psoriatic Arthritis  Patient Share (%) Overview at a Glance<\/p>\n

          5. Psoriatic Arthritis  Market Overview at a Glance<\/p>\n

          6. Psoriatic Arthritis  Disease Background and Overview<\/p>\n

          7. Psoriatic Arthritis  Epidemiology and Patient Population<\/p>\n

          8. Country-Specific Patient Population of Psoriatic Arthritis <\/p>\n

          9. Psoriatic Arthritis  Current Treatment and Medical Practices<\/p>\n

          10. Unmet Needs<\/p>\n

          11. Psoriatic Arthritis  Emerging Therapies<\/p>\n

          12. Psoriatic Arthritis  Market Outlook<\/p>\n

          13. Country-Wise Psoriatic Arthritis  Market Analysis (2017–2030)<\/p>\n

          14. Market Access and Reimbursement of Therapies<\/p>\n

          15. Market drivers<\/p>\n

          16. Market barriers<\/p>\n

          17. Appendix<\/p>\n

          18. Psoriatic Arthritis  Report Methodology<\/p>\n

          19. DelveInsight Capabilities<\/p>\n

          20. Disclaimer<\/p>\n

          21. About DelveInsight<\/p>\n

          Related Reports:<\/strong><\/p>\n

          Psoriatic Arthritis Pipeline <\/a><\/strong><\/p>\n

          “Psoriatic Arthritis Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the  Psoriatic Arthritis market. A detailed picture of the  Psoriatic Arthritis pipeline landscape is provided, which includes the disease overview and  Psoriatic Arthritis treatment guidelines.<\/p>\n

          Psoriatic Arthritis Epidemiology<\/a><\/strong><\/p>\n

          DelveInsight’s ‘Psoriatic Arthritis  Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Psoriatic Arthritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

          Media Contact<\/span>
          Company Name:<\/strong>           DelveInsight Business Research LLP<\/a>
          Contact Person:<\/strong> Kritika Rehani
          Email:<\/strong>           Send Email<\/a>
          Phone:<\/strong> 9193216187
          Address:<\/strong>304 S. Jones Blvd #2432
          City:<\/strong> Las Vegas
          State:<\/strong> Nevada
          Country:<\/strong> United States
          Website:<\/strong>           https:\/\/www.delveinsight.com\/<\/a><\/p>\n

          <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

          DelveInsight Business Research LLP DelveInsight\u2019s \u2018Psoriatic Arthritis (PsA)\u2013 Market Insights, Epidemiology, and Market Forecast\u20142030\u2019 report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Psoriatic Arthritis in the United States, EU5 (Germany, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-556994","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/556994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=556994"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/556994\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=556994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=556994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=556994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}